Prothena Corporation plc
Research Prothena Corporation plc (PRTA) on Bullrun: market cap USD 487.43M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRTA
- ExchangeNASDAQ
- CountryIreland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 487.43M
- Financial periodQ2 2026
- RevenueUSD 1.01M
- Net income-USD 18.58M
- Free cash flow-USD 25.70M
Valuation Snapshot
latest market cap is USD 487.43M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 9.68M | -USD 244.09M | -USD 163.72M | n/a | -4.53 | USD 307.53M | USD 8.37M | USD 280.47M |
| FY2024 | USD 135.16M | -USD 122.31M | -USD 150.35M | n/a | -2.27 | USD 471.39M | USD 10.84M | USD 486.93M |
| FY2023 | USD 91.37M | -USD 147.03M | n/a | n/a | -2.76 | USD 618.83M | USD 11.84M | USD 561.37M |
| FY2022 | USD 53.91M | -USD 116.95M | n/a | n/a | -2.47 | USD 710.41M | USD 9.58M | USD 622.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 487.43M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 514.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 745.50M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.95B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.11B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.31B | 45.3 | n/a | n/a |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Prothena Corporation plc's market cap?
Prothena Corporation plc's market capitalization is USD 487.43M.
What does Prothena Corporation plc do?
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.